You Won't Regret Reading the Facts on DexCom

Large-cap Healthcare company DexCom has logged a -4.2% change today on a trading volume of 891,774. The average volume for the stock is 2,718,401.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. Based in San Diego, United States the company has 6,300 full time employees and a market cap of $10,748,649,472.

The company is now trading -14.8% away from its average analyst target price of $130.17 per share. The 18 analysts following the stock have set target prices ranging from $103 to $150, and on average give DexCom a rating of buy.

Over the last year, DXCM shares have gone up 0.2%, which represents a difference of 16.8% when compared to the S&P 500. The stock's 52 week high is $134.76 per share whereas its 52 week low is $66.89. Based on DexCom's strng revenue growth over the last four years, its core business remains strong and the stock price may maintain this level of performance.

2019-12-31 2020-12-31 2021-12-31
Revenue (MM) $1,476 $1,927 $2,448
Revenue Growth n/a 30.54% 27.08%
Gross Margins 63.1% 66.4% 68.6%
Gross Margins Growth n/a 5.23% 3.31%
Operating Margins 9.6% 15.5% 10.9%
Operating Margins Growth n/a 61.46% -29.68%
Earnings Per Share $0.28 $1.26 $0.39
EPS Growth n/a 350.0% -69.05%
Free Cash Flow (MM) $134 $277 $53
FCF Growth n/a 105.65% -80.73%
Capital Expenditures (MM) -$180 -$199 -$389
Net Debt / EBITDA 2.94 2.26 1.77
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.